Osvely Méndez-Guerrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Osvely Méndez-Guerrero has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Nalu Navarro-Alvarez
Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 15 Vasco de Quiroga, Mexico city, 14080, Mexico.
3 shared publications Aldo Torre
Department of Gastroenterology, Hepatology and Liver Transplantation Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico
2 shared publications- Aldo Torre
Gastroenterology Department ABC Medical Center Mexico City Mexico
2 shared publications - Eduardo Cervantes-Alvarez
Department of Internal Medicine B, University Hospital Münster, Münster, Germany
2 shared publications - Nathaly Limon-De la Rosa
Department of Gastroenterology, Hepatology and Liver Transplantation Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico
2 shared publications A. Torre
Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
1 shared publication
Latest Publications
- 28 May 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1)
Zinc deficiency and sarcopenia define a metabolic frailty phenotype predicting hepatic encephalopathy and early mortality in cirrhosis
Cirrhosis is characterized by progressive metabolic vulnerability, yet early indicators of clinical decompensation remain limited. Zinc, a key cofactor in ammonia detoxification and protein metabolism, may reflect and contribute to metabolic frailty when deficient. We aimed to determine whether zinc deficiency and sarcopenia jointly define a metabolic frailty phenotype that predicts overt hepatic encephalopathy (OHE) and mortality in cirrhosis. In this 12-month prospective cohort, 109 adults with cirrhosis were followed to evaluate OHE incidence and survival. Serum zinc, dietary intake, and nutritional parameters were assessed at baseline and 3, 6, and 12 months. Sarcopenia was defined by dual-energy X-ray absorptiometry and handgrip strength. Logistic regression identified independent predictors of OHE, and Kaplan-Meier analysis evaluated survival. OHE occurred in 27.5% of patients and was associated with lower zinc levels (50.3 ± 13.2 vs. 62.8 ± 18.9 µg/dL; p = 0.002) and higher sarcopenia prevalence (53.3% vs. 16.5%; p = 0.001). Zinc deficiency was associated with increased OHE risk (OR 3.9; 95% CI 1.5-10.1; p = 0.005), while multivariable analysis identified sarcopenia, age, and Child-Pugh class as independent predictors. The coexistence of zinc deficiency and sarcopenia identified a subgroup with the highest 1-year mortality (log-rank p = 0.001). Zinc deficiency and sarcopenia were associated with adverse clinical outcomes in cirrhosis and may reflect a broader state of metabolic vulnerability. Their coexistence defines a metabolic frailty phenotype in cirrhosis, associated with reduced metabolic reserve, OHE, and poor survival. Recognition of this phenotype provides a framework for targeted nutritional and metabolic interventions aimed at restoring functional reserve.
- 28 May 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1)
Zinc deficiency and sarcopenia define a metabolic frailty phenotype predicting hepatic encephalopathy and early mortality in cirrhosis
Cirrhosis is characterized by progressive metabolic vulnerability, yet early indicators of clinical decompensation remain limited. Zinc, a key cofactor in ammonia detoxification and protein metabolism, may reflect and contribute to metabolic frailty when deficient. We aimed to determine whether zinc deficiency and sarcopenia jointly define a metabolic frailty phenotype that predicts overt hepatic encephalopathy (OHE) and mortality in cirrhosis. In this 12-month prospective cohort, 109 adults with cirrhosis were followed to evaluate OHE incidence and survival. Serum zinc, dietary intake, and nutritional parameters were assessed at baseline and 3, 6, and 12 months. Sarcopenia was defined by dual-energy X-ray absorptiometry and handgrip strength. Logistic regression identified independent predictors of OHE, and Kaplan-Meier analysis evaluated survival. OHE occurred in 27.5% of patients and was associated with lower zinc levels (50.3 ± 13.2 vs. 62.8 ± 18.9 µg/dL; p = 0.002) and higher sarcopenia prevalence (53.3% vs. 16.5%; p = 0.001). Zinc deficiency was associated with increased OHE risk (OR 3.9; 95% CI 1.5-10.1; p = 0.005), while multivariable analysis identified sarcopenia, age, and Child-Pugh class as independent predictors. The coexistence of zinc deficiency and sarcopenia identified a subgroup with the highest 1-year mortality (log-rank p = 0.001). Zinc deficiency and sarcopenia were associated with adverse clinical outcomes in cirrhosis and may reflect a broader state of metabolic vulnerability. Their coexistence defines a metabolic frailty phenotype in cirrhosis, associated with reduced metabolic reserve, OHE, and poor survival. Recognition of this phenotype provides a framework for targeted nutritional and metabolic interventions aimed at restoring functional reserve.
- Top Cited PapersOpen Access
- 21 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 91-105
Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts
- 21 February 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 91-105
Top Cited PapersOpen AccessDevelopment and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts
- 12 June 2022
- Published by Wiley in Liver International
- Vol. 42 (10) , 2260-2273
Galectin‐3 is overexpressed in advanced cirrhosis and predicts post‐liver transplant infectious complications
Background & Aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin‐3 is a β‐galactoside‐binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin‐3 expression in advanced cirrhosis and its ability to predict post‐transplant infectious complications.Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin‐3 was assessed by ELISA, real‐time PCR, immunohistochemistry and RNA‐seq. Receiver operating characteristic curves and Cox proportional‐hazards regression analysis were performed to assess the predictive power of galectin‐3 for disease severity and post‐transplant infections.Results: Increased galectin‐3 levels were found in advanced cirrhosis. Galectin‐3 significantly correlated with disease severity parameters and inflammatory markers. Galectin‐3 had significant discriminating power for compensated and advanced cirrhosis (AUC = 0.78/0.84, circulating/liver galectin‐3; p < .01), and was even higher to discriminate severe AH (AUC = 0.95, p < .0001). Cox Proportional‐hazard model showed that galectin‐3, MELD‐Na and the presence of SIRS predict the development of post‐transplant infectious complications. Patients with circulating galectin‐3 (>16.58 ng/ml) were at 2.19‐fold 95% CI (1.12–4.29) increased risk, but when combined with MELD‐Na > 20.0 and SIRS, the risk to develop post‐transplant infectious complications, increased to 4.60, 95% CI (2.38–8.90).Conclusion: Galectin‐3 is a novel biological marker of active inflammation and disease severity that could be clinically useful alone or in combination with other scores to discriminate advanced cirrhosis and predict post‐transplant infectious complications.
- 12 June 2022
- Published by Wiley in Liver International
- Vol. 42 (10) , 2260-2273
Galectin‐3 is overexpressed in advanced cirrhosis and predicts post‐liver transplant infectious complications
Background & Aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin‐3 is a β‐galactoside‐binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin‐3 expression in advanced cirrhosis and its ability to predict post‐transplant infectious complications.Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin‐3 was assessed by ELISA, real‐time PCR, immunohistochemistry and RNA‐seq. Receiver operating characteristic curves and Cox proportional‐hazards regression analysis were performed to assess the predictive power of galectin‐3 for disease severity and post‐transplant infections.Results: Increased galectin‐3 levels were found in advanced cirrhosis. Galectin‐3 significantly correlated with disease severity parameters and inflammatory markers. Galectin‐3 had significant discriminating power for compensated and advanced cirrhosis (AUC = 0.78/0.84, circulating/liver galectin‐3; p < .01), and was even higher to discriminate severe AH (AUC = 0.95, p < .0001). Cox Proportional‐hazard model showed that galectin‐3, MELD‐Na and the presence of SIRS predict the development of post‐transplant infectious complications. Patients with circulating galectin‐3 (>16.58 ng/ml) were at 2.19‐fold 95% CI (1.12–4.29) increased risk, but when combined with MELD‐Na > 20.0 and SIRS, the risk to develop post‐transplant infectious complications, increased to 4.60, 95% CI (2.38–8.90).Conclusion: Galectin‐3 is a novel biological marker of active inflammation and disease severity that could be clinically useful alone or in combination with other scores to discriminate advanced cirrhosis and predict post‐transplant infectious complications.
- Open Access
Time-Dependent Changes of Laboratory Parameters as Independent Predictors of All-Cause Mortality in COVID-19 Patients
Independent predictors of mortality for COVID-19 patients have been identified upon hospital admission; however, how they behave after hospitalization remains unknown. The aim of this study is to identify clinical and laboratory parameters from admission to discharge or death that distinguish survivors and non-survivors of COVID-19, including those with independent ability to predict mortality. In a cohort of 266 adult patients, clinical and laboratory data were analyzed from admission and throughout hospital stay until discharge or death. Upon admission, non-survivors had significantly increased C reactive protein (CRP), neutrophil count, neutrophil to lymphocyte ratio (NLR) (p < 0.0001, each), ferritin (p < 0.001), and AST (aspartate transaminase) (p = 0.009) compared to survivors. During the hospital stay, deceased patients maintained elevated CRP (21.7 mg/dL [admission] vs. 19.3 [hospitalization], p = 0.060), ferritin, neutrophil count and NLR. Conversely, survivors showed significant reductions in CRP (15.8 mg/dL [admission] vs. 9.3 [hospitalization], p < 0.0001], ferritin, neutrophil count and NLR during hospital stay. Upon admission, elevated CRP, ferritin, and diabetes were independent predictors of mortality, as were persistently high CRP, neutrophilia, and the requirement of invasive mechanical ventilation during hospital stay. Inflammatory and clinical parameters distinguishing survivors from non-survivors upon admission changed significantly during hospital stay. These markers warrant close evaluation to monitor and predict patients’ outcome once hospitalized.
Open AccessTime-Dependent Changes of Laboratory Parameters as Independent Predictors of All-Cause Mortality in COVID-19 Patients
Independent predictors of mortality for COVID-19 patients have been identified upon hospital admission; however, how they behave after hospitalization remains unknown. The aim of this study is to identify clinical and laboratory parameters from admission to discharge or death that distinguish survivors and non-survivors of COVID-19, including those with independent ability to predict mortality. In a cohort of 266 adult patients, clinical and laboratory data were analyzed from admission and throughout hospital stay until discharge or death. Upon admission, non-survivors had significantly increased C reactive protein (CRP), neutrophil count, neutrophil to lymphocyte ratio (NLR) (p < 0.0001, each), ferritin (p < 0.001), and AST (aspartate transaminase) (p = 0.009) compared to survivors. During the hospital stay, deceased patients maintained elevated CRP (21.7 mg/dL [admission] vs. 19.3 [hospitalization], p = 0.060), ferritin, neutrophil count and NLR. Conversely, survivors showed significant reductions in CRP (15.8 mg/dL [admission] vs. 9.3 [hospitalization], p < 0.0001], ferritin, neutrophil count and NLR during hospital stay. Upon admission, elevated CRP, ferritin, and diabetes were independent predictors of mortality, as were persistently high CRP, neutrophilia, and the requirement of invasive mechanical ventilation during hospital stay. Inflammatory and clinical parameters distinguishing survivors from non-survivors upon admission changed significantly during hospital stay. These markers warrant close evaluation to monitor and predict patients’ outcome once hospitalized.
- Open Access
- 1 October 2018
- Published by Elsevier in Revista de Gastroenterología de México
- Vol. 83 (4) , 424-433
Manejo dietético y suplementación con aminoácidos de cadena ramificada en cirrosis hepática
- 1 October 2018
- Published by Elsevier in Revista de Gastroenterología de México
- Vol. 83 (4) , 424-433
Open AccessManejo dietético y suplementación con aminoácidos de cadena ramificada en cirrosis hepática
- 24 February 2018
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 24 (5) , 595-605
Fibroblast growth factor 21 is an early predictor of acute‐on‐chronic liver failure in critically ill patients with cirrhosis
Acute‐on‐chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation). This study evaluated fibroblast growth factor 21 (FGF21) as a marker of mitochondrial dysfunction in the context of ACLF. The study included 154 individuals (112 critically patients and 42 healthy controls) divided into a training and a validation cohort. In the training cohort of 42 healthy controls and 34 critically ill patients (of whom 24 were patients with cirrhosis), levels of FGF21, interleukin (IL) 6, and IL8 were measured. In the validation cohort of 78 patients with cirrhosis, 17 patients were admitted with or developed ACLF during follow‐up and underwent daily clinical and nutritional assessment. Levels of FGF21 were higher in critically ill patients, especially in patients with cirrhosis admitted to the intensive care unit (ICU). Moreover, FGF21 as well as IL6 and IL8 levels were higher in patients with ACLF, but they did not increase with the severity of ACLF. Interestingly, in the validation cohort, FGF21 was also elevated in the patients who developed ACLF in the next 7 days. In these patients, FGF21 levels were an independent predictor of ACLF presence and development in multivariate analysis together with Child‐Pugh score. FGF21 levels had no impact on the survival of critically ill patients with cirrhosis. In conclusion, this study demonstrates that FGF21 levels are of specific diagnostic value regarding the presence and development of ACLF in patients admitted to ICU for AD of liver cirrhosis. Further studies are warranted to address pathophysiological and possible therapeutic implications. Liver Transplantation 24 595–605 2018 AASLD.
- 24 February 2018
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 24 (5) , 595-605
Fibroblast growth factor 21 is an early predictor of acute‐on‐chronic liver failure in critically ill patients with cirrhosis
Acute‐on‐chronic liver failure (ACLF) develops in acute decompensation (AD) of cirrhosis and shows high mortality. In critically ill patients, early diagnosis of ACLF could be important for therapeutic decisions (eg, renal replacement, artificial liver support, liver transplantation). This study evaluated fibroblast growth factor 21 (FGF21) as a marker of mitochondrial dysfunction in the context of ACLF. The study included 154 individuals (112 critically patients and 42 healthy controls) divided into a training and a validation cohort. In the training cohort of 42 healthy controls and 34 critically ill patients (of whom 24 were patients with cirrhosis), levels of FGF21, interleukin (IL) 6, and IL8 were measured. In the validation cohort of 78 patients with cirrhosis, 17 patients were admitted with or developed ACLF during follow‐up and underwent daily clinical and nutritional assessment. Levels of FGF21 were higher in critically ill patients, especially in patients with cirrhosis admitted to the intensive care unit (ICU). Moreover, FGF21 as well as IL6 and IL8 levels were higher in patients with ACLF, but they did not increase with the severity of ACLF. Interestingly, in the validation cohort, FGF21 was also elevated in the patients who developed ACLF in the next 7 days. In these patients, FGF21 levels were an independent predictor of ACLF presence and development in multivariate analysis together with Child‐Pugh score. FGF21 levels had no impact on the survival of critically ill patients with cirrhosis. In conclusion, this study demonstrates that FGF21 levels are of specific diagnostic value regarding the presence and development of ACLF in patients admitted to ICU for AD of liver cirrhosis. Further studies are warranted to address pathophysiological and possible therapeutic implications. Liver Transplantation 24 595–605 2018 AASLD.
- Open Access
- 1 November 2016
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 12, 1729-1748
Intestinal permeability in a patient with liver cirrhosis
Liver cirrhosis is a worldwide public health problem, and patients with this disease are at high risk of developing complications, bacterial translocation from the intestinal lumen to the mesenteric nodes, and systemic circulation, resulting in the development of severe complications related to high mortality rate. The intestinal barrier is a structure with a physical and biochemical activity to maintain balance between the external environment, including bacteria and their products, and the internal environment. Patients with liver cirrhosis develop a series of alterations in different components of the intestinal barrier directly associated with the severity of liver disease that finally increased intestinal permeability. A “leaky gut” is an effect produced by damaged intestinal barrier; alterations in the function of tight junction proteins are related to bacterial translocation and their products. Instead, increasing serum proinflammatory cytokines and hemodynamics modification, which results in the appearance of complications of liver cirrhosis such as hepatic encephalopathy, variceal hemorrhage, bacterial spontaneous peritonitis, and hepatorenal syndrome. The intestinal microbiota plays a fundamental role in maintaining the proper function of the intestinal barrier; bacterial overgrowth and dysbiosis are two phenomena often present in people with liver cirrhosis favoring bacterial translocation. Increased intestinal permeability has an important role in the genesis of these complications, and treating it could be the base for prevention and partial treatment of these complications.
- 1 November 2016
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 12, 1729-1748
Open AccessIntestinal permeability in a patient with liver cirrhosis
Liver cirrhosis is a worldwide public health problem, and patients with this disease are at high risk of developing complications, bacterial translocation from the intestinal lumen to the mesenteric nodes, and systemic circulation, resulting in the development of severe complications related to high mortality rate. The intestinal barrier is a structure with a physical and biochemical activity to maintain balance between the external environment, including bacteria and their products, and the internal environment. Patients with liver cirrhosis develop a series of alterations in different components of the intestinal barrier directly associated with the severity of liver disease that finally increased intestinal permeability. A “leaky gut” is an effect produced by damaged intestinal barrier; alterations in the function of tight junction proteins are related to bacterial translocation and their products. Instead, increasing serum proinflammatory cytokines and hemodynamics modification, which results in the appearance of complications of liver cirrhosis such as hepatic encephalopathy, variceal hemorrhage, bacterial spontaneous peritonitis, and hepatorenal syndrome. The intestinal microbiota plays a fundamental role in maintaining the proper function of the intestinal barrier; bacterial overgrowth and dysbiosis are two phenomena often present in people with liver cirrhosis favoring bacterial translocation. Increased intestinal permeability has an important role in the genesis of these complications, and treating it could be the base for prevention and partial treatment of these complications.